Drug Profile


Alternative Names: PPL-1

Latest Information Update: 25 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pitney Pharmaceuticals
  • Developer PharmAust
  • Class Acetonitriles; Anthelmintics; Antineoplastics
  • Mechanism of Action Cyclin-dependent kinase 2 modulators; Cyclin-dependent kinase 4 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 01 Aug 2016 Phase-I/II development is ongoing in Australia
  • 17 Jun 2014 Phase-I/II clinical trials in Solid tumours (refractory metastatic disease, second-line therapy or greater) in Australia (PO)
  • 25 Jul 2013 Pitney Pharmaceuticals and an undisclosed company agree to co-develop monepantel in Australia for cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top